Though it starts out as a discussion of the Collegium Ramazzini’s call for "a global ban on asbestos" the interview with Dr. Lemen in this month’s EHP quickly turns to new frontiers in the litigation (e.g. ovarian cancer), the nefarious impact of profits on corporations (and not individuals, apparently) , the implication that chrysotile is worse than amphibole asbestos, and an argument that we already know everything we need to know about asbestos and so shouldn’t waste any more "research dollars" on studying the issue.

Read about it here or listen to the Podcast .